Drug Trial Radar · NCT06360874
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
104
Planned (sponsor's estimate)
Start
May 9, 2024
Primary completion
Dec 2024
Study completion Feb 2025
Sponsor
- Lead sponsor
- Shenzhen NewDEL Biotech, Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults
Conditions
- Healthy
Interventions
ND-003 40mgDrug
Participants receive 40mg ND-003 tablets once.
ND-003 placebo 40mgDrug
Participants receive placebo tablet matching to receive 40mg of ND-003.
ND-003 80mgDrug
Participants receive 80mg ND-003 tablets once.
ND-003 placebo 80mgDrug
Participants receive placebo tablet matching to receive 80mg of ND-003.
ND-003 160mgDrug
Participants receive 160mg ND-003 tablets once.
ND-003 placebo 160mgDrug
Participants receive placebo tablet matching to receive 160mg of ND-003.
ND-003 240mgDrug
Participants receive 240mg ND-003 tablets once.
ND-003 placebo 240mgDrug
Participants receive placebo tablet matching to receive 240mg of ND-003.
ND-003 300mgDrug
Participants receive 300mg ND-003 tablets once.
ND-003 placebo 300mgDrug
Participants receive placebo tablet matching to receive 300mg of ND-003.
MAD_ND003_Dose 1Drug
Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
MAD_placebo_Dose 1Drug
Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 1
MAD_ND003_Dose 2Drug
Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
MAD_placebo_Dose 2Drug
Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 2
MAD_ND003_Dose 3Drug
Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
MAD_ placebo_Dose 3Drug
Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 3
Food effect_Cohort 1Drug
Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Food effect_Cohort 2Drug
Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AE)Time frame: through study completion, an average of 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.